Reference Center for Haemophilia and Coagulation Disorders

Reference Center for Haemophilia and Coagulation Disorders provides urgent, day-to-day and long-term diagnostic and treatment services:

• Congenital hemophilia A and B

• Acquired hemophilia

• von Willebrand disease

• Other rare congenital and acquired coagulation factor deficiencies

• Thrombocytopathies

• Congenital and acquired thrombophilia

Biomedical research of the center:

• Safety and efficacy of N8 in the prevention of bleeding episodes in haemophilia A and in the control of bleeding episodes if necessary.

• A multicenter, phase III, uncontrolled, open-label study to evaluate the safety and efficacy of prophylactic therapy with BAY 81-8973 in children with severe haemophilia A.

• A prospective, international, non-interventional, post-marketing study to demonstrate the long-term immunogenicity, safety, and efficacy of recombinant human coagulation factor VIII (simoctocog alfa) in patients with haemophilia A who are receiving standard clinical therapy.

• Immune Tolerance Induction Assay (ObsITI Assay).

• Clinical and genetic risk factors in children and adolescents with thromboembolism treated with the NOPHO ALL 2008 protocol: a case-control study.

• Clinical and genetic risk factors in children and adolescents with thromboembolism treated with the NOPHO ALL 2008 protocol: a case-control study.

Reference Center for Haemophilia and Coagulation Disorders provides qualified consultations from a pediatric oncohematologist, adult hematologist and various other specialists working in other departments of VUH Santaros klinikos: laboratory physicians, medical geneticists, obstetricians, gynecologists, orthopedists, gastrologists, radiologists , urologists and rehabilitation doctors.